Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BLTE | US
-0.25
-0.55%
Healthcare
Biotechnology
31/03/2024
05/07/2024
45.50
45.53
45.77
44.91
Belite Bio Inc a clinical stage biopharmaceutical drug development company engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant) an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009 an anti-retinol binding protein 4 oral therapy targeting liver disease including non-alcoholic fatty liver disease nonalcoholic steatohepatitis type 2 diabetes and gout which is in the preclinical development phase. Belite Bio Inc was founded in 2016 and is based in San Diego California. Belite Bio Inc operates as a subsidiary of Lin Bioscience International Ltd.
View LessStrong Sharpe Ratio (> 1.2)
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
15.9%1 month
16.8%3 months
42.4%6 months
46.7%-
-
12.11
-
-
-32.31
-
-
-32.96M
1.36B
1.36B
-
-
-
-
-49.54
0.57
0.30
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.16
Range1M
5.24
Range3M
19.14
Rel. volume
0.97
Price X volume
3.39M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Akero Therapeutics Inc | AKRO | Biotechnology | 21.45 | 1.48B | -2.19% | n/a | 4.28% |
Dynavax Technologies Corporation | DVAX | Biotechnology | 11.25 | 1.47B | 2.09% | 160.43 | 41.41% |
Array BioPharma Inc | ARRY | Biotechnology | 9.62 | 1.46B | -4.85% | 27.00 | 114.13% |
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 14.78 | 1.42B | 1.72% | n/a | 46.87% |
MannKind Corporation | MNKD | Biotechnology | 5.13 | 1.40B | 1.99% | 130.50 | -162.73% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 20.21 | 1.39B | 3.22% | n/a | 12.31% |
Kiniksa Pharmaceuticals Ltd | KNSA | Biotechnology | 19.36 | 1.37B | 1.36% | 143.62 | 2.81% |
Longboard Pharmaceuticals Inc. Common Stock | LBPH | Biotechnology | 34.87 | 1.36B | 9.28% | n/a | 1.27% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 6.52 | 1.35B | 1.72% | n/a | -173.65% |
Verona Pharma plc | VRNA | Biotechnology | 16.11 | 1.31B | 2.55% | n/a | 22.79% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Steelcase Inc | SCS | Building Products & Equipment | 12.82 | 1.46B | -0.93% | 17.05 | 69.98% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.45 | 1.31B | -0.37% | n/a | 20.15% |
REV Group Inc | REVG | Recreational Vehicles | 24.74 | 1.28B | -2.06% | 5.86 | 66.74% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.36 | 1.14B | 1.60% | n/a | -628.58% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 17.73 | 799.13M | -2.42% | n/a | 4070.84% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -32.31 | -2.43 | Cheaper |
Ent. to Revenue | - | 4,101.76 | - |
PE Ratio | - | 41.26 | - |
Price to Book | 12.11 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 42.40 | 76.52 | Lower Risk |
Debt to Equity | - | 0.51 | - |
Debt to Assets | - | 0.24 | - |
Market Cap | 1.36B | 3.77B | Emerging |